Highlights in myasthenia gravis from AANEM 2024 include efficacy data on efgartigimod, ravulizumab, zilucoplan, and first-in-class inebilizumab, as well as safety outcomes in pregnancy for eculizumab.

Increased demands from an aging population and pandemic-related supply shortages leave provinces scrambling to allocate ...

Patients with celiac disease who take an angiotensin receptor blocker (ARB) may experience worse outcomes, such as iron ...

The US Food and Drug Administration (FDA) sometimes allows cancer drugs with accelerated approvals to remain on the market ...

Phase 3 study on previously untreated chronic lymphocytic leukemia showed sustained PFS with venetoclax-obinutuzumab.